Ozempic Gastroparesis Settlement: Key Factors in Claim Valuation

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Risk Assessment

For decades, general health and science information has served as the foundation for public understanding of medical treatments and their broader implications. This legacy context emphasized the importance of informed decision-making, risk awareness, and the balance between therapeutic benefits and potential adverse effects. Within this framework, discussions around pharmaceutical interventions naturally evolved to include not only efficacy but also the spectrum of patient experiences and outcomes. As the landscape of mass production in healthcare expands, the focus shifts from abstract health principles to specific, real-world exposures. The widespread use of medications such as Ozempic, originally developed for metabolic conditions, has introduced new considerations regarding long-term safety profiles. In particular, attention has turned to the potential for gastrointestinal complications, including gastroparesis, arising from sustained exposure. This pivot from general health education to occupational and patient-level exposure concerns reflects a necessary evolution in how we assess risk. The transition requires examining the factors that influence claims related to such exposures, moving beyond broad health literacy toward a more targeted evaluation of individual circumstances and liability.

Find Out If You Qualify for Compensation →

Bridging General Principles to Ozempic-Specific Risks

Building on the legacy of informed decision-making, the specific case of Ozempic (semaglutide) illustrates how general health principles apply to a particular pharmaceutical. Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Its pharmacological action includes slowing gastric emptying, a mechanism that can contribute to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction—has emerged as a significant concern in both clinical trials and post-marketing surveillance. Clinical presentation of gastroparesis includes early satiety, postprandial fullness, nausea, vomiting, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath testing to confirm delayed emptying. In the context of Ozempic use, these symptoms may overlap with common gastrointestinal reactions reported in clinical trials.

Clinical Trial Evidence and Dose-Dependent Gastrointestinal Effects

In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal intolerance, which may be relevant to gastroparesis risk.

Post-Marketing Surveillance and Mechanistic Link to Gastroparesis

Post-marketing data from the FDA Adverse Event Reporting System (FAERS) further highlight the association. Among adverse-event reports most frequently associated with Ozempic, impaired gastric emptying was reported in 2,693 cases, alongside nausea (8,652 reports), vomiting (5,578 reports), and dyspepsia (1,374 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). The presence of impaired gastric emptying as a distinct reported term supports a mechanistic link between Ozempic and gastroparesis. The GLP-1 receptor agonist class slows gastric motility, and prolonged use may lead to symptomatic gastroparesis in susceptible individuals. From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a key factor in settlement considerations. The prescribing information for Ozempic includes gastrointestinal adverse reactions as a class effect, but does not explicitly list gastroparesis as a separate warning. Patients who develop gastroparesis after Ozempic use may argue that the risk was not adequately communicated, particularly given the severity and chronic nature of the condition.

Settlement Valuation Factors and Legal Considerations

Settlement-related considerations for affected patients include the strength of the causal link, the severity of harm, and the timeline between exposure and documented harm. The FAERS data show a substantial number of reports of impaired gastric emptying, which may support individual claims. The timeline between exposure and harm is critical. In clinical trials, gastrointestinal symptoms often emerged during dose escalation, but gastroparesis may develop after months or years of use. Patients who experience persistent symptoms after discontinuation may have a stronger claim, as drug-induced gastroparesis can be irreversible in some cases. Settlement valuation factors include medical costs, lost income, pain and suffering, and the degree of disability. Cases with clear documentation of delayed gastric emptying via objective testing, and a temporal relationship to Ozempic initiation, are likely to be valued higher. In summary, the evidence from clinical trials and FAERS data supports a plausible link between Ozempic and gastroparesis. The mechanism involves GLP-1 receptor-mediated slowing of gastric emptying, which can become pathological. Settlement considerations hinge on warning adequacy, severity of harm, and the strength of the causal connection. Patients with confirmed gastroparesis after Ozempic use should seek legal counsel to evaluate their individual circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism, which can lead to gastroparesis in some patients. Clinical trials show dose-dependent gastrointestinal adverse reactions, and post-marketing FAERS data report thousands of cases of impaired gastric emptying associated with Ozempic. The prescribing information does not explicitly warn about gastroparesis, which may be relevant for claims.

What factors affect the valuation of an Ozempic gastroparesis claim?

Key factors include the strength of the causal link (e.g., documented delayed gastric emptying via objective testing), severity of harm (medical costs, lost income, pain and suffering), timeline between Ozempic use and symptom onset, and whether symptoms persist after discontinuation. Cases with clear documentation and a temporal relationship are valued higher.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.